Back to results
US 6,440,946 B1Granted
Multiple-agents-binding compound, production and use thereof
AssigneeTakeda Chemical Industries, Ltd.
InventorsYoshiaki Kiso, Masahiko Fujino
Life of this patent
Estimating the term…
Abstract
The present invention is to provide a multiple-agents-binding compound comprising a compound having anti-HIV activity and having no affinity for cell surface protein bound together with a same or different kind of at least one compound having anti-HIV activity and having no affinity for cell surface protein, or a salt thereof, and a pharmaceutical composition for the prevention or treatment of infectious diseases of HIV or AIDS comprising said multiple-agents-binding compound.
Claims24
A compound comprising:
- at least two compounds having anti-HIV activity and having no affinity for cell surface proteins;
- said compounds bound together with at least one linkage selected from the group consisting of an —OC(O)— linkage, an amide linkage, an ether linkage and a disulfide linkage.
A compound comprising:
- an HIV reverse transcriptase inhibitor and an HIV protease inhibitor;
- said HIV reverse transcriptase inhibitor and said HIV protease inhibitor bound together with at least one linkage selected from the group consisting of an —OC(O)— linkage, an amide linkage, an ether linkage and a disulfide linkage.
A compound selected from the group consisting of:
- a compound of the formula:
- wherein R is a C1-6 alkyl group or an unsubstituted or substituted phenyl-C1-3 alkyl group,
- R1 and R2 are independently a hydrogen atom or a C1-6 alkyl group, and
- X is an unsubstituted or substituted C1-6 alkylene group;
- a compound of the formula:
- wherein R is a C1-6 alkyl group or an unsubstituted or substituted phenyl-C1-3 alkyl group,
- R1 and R2 are independently a hydrogen atom or a C1-6 alkyl group,
- X is an unsubstituted or substituted C1-6 alkylene group, and the ring A is an unsubstituted or substituted benzene ring,
- and salts thereof.
6 more elements
A compound comprising:
- an HIV reverse transcriptase inhibitor and an HIV protease inhibitor;
- said HIV reverse transcriptase inhibitor and said HIV protease inhibitor bound together through a spacer;
- wherein said spacer is a cyclic or acyclic group having at least two linkages,
- wherein each linkage is independently selected from the group consisting of an —OC(O)— linkage, an amide linkage, an ether linkage and a disulfide linkage.
1 more element
Dependencies are inferred from the claim text.